Comparison of the Efficacy and Safety of Risperidone Versus Risperidone Plus Low Dose of Haloperidol in the Treatment of Schizophrenia

Phase 4

Terminated

• Conditions: Schizophrenia
• Interventions: Drug: risperidone

• Registration Number: NCT00998608
• Lead Sponsor: Kaohsiung Kai-Suan Psychiatric Hospital

Brief Summary

The purpose of this study is to compare the efficacy and safety of risperidone and risperidone plus low dose of haloperidol in the acutely schizophrenic patients.

Detailed Description

Antipsychotic monotherapy is recognized as the treatment of choice for patients with schizophrenia. Surveys have shown that antipsychotic drug combinations are frequently prescribed, yet few clinical studies have examined this practice. Risperidone, an atypical antipsychotics, has low incidence of extrapyramidal symptom (EPS) but with high cost compared to haloperidol. It has been reported that a relatively low daily dose of haloperidol at which individual patients develop slightly increase in EPS and has neurocognitive benefits as risperidone. The objective of the study is to compare the efficacy and safety of the fixed-dosed risperidone and risperidone combined with haloperidol in the treatment of acute psychotic exacerbations of schizophrenia.In this 6-week, double-blind, fixed-dose study, patients with schizophrenic disorder (DSM-IV diagnosis) are randomly assigned to risperidone (4 mg/d) or risperidone (2 mg/d) plus haloperidol (2 mg/d). The hypothesis is that the two treatment groups have the similar efficacy and safety, but different cost. The primary efficacy measure is change from baseline in Positive and Negative Syndrome Scale (PANSS) total scores; secondary outcomes include Clinical Global Impression-Change (CGI-C), the Calgary Depression Scale for Schizophrenics (CDSS), subject-reported outcomes via the Short Form-36 (SF-36), auditory evoked potentials (AEPs), and cognitive and social functioning. Safety assessments include the change from baseline on Simpson-Angus Rating Scale (SAS), Abnormal Involuntary Movement Scale (AIMS), Barnes Akathisia Scale (BAS), and UKU Side-effects Rating Scale (UKU), and the change from baseline in prolactin levels, body weight, AC glucose level, lipid panel (cholesterol, high density lipid protein \[HDL\], low density lipid protein \[LDL\], and triglyceride \[TG\])

Study Timeline

• Study Start: 2007-08
• Primary Completion: 2009-07
• Status Verified: 2009-10
• Study Completion: 2009-10
• Study First Submitted: 2009-10-08
• Study First Submitted QC: 2009-10-18
• Last Update Submitted: 2009-10-18
• Study First Posted: 2009-10-20
• Last Update Posted: 2009-10-20

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 88

Inclusion Criteria

• Diagnosis of schizophrenia
• Clinical Global Impression large than 3
• Written informed consent

Exclusion Criteria

• Comorbid of substance abuse/dependence
• Present or history of tardive dyskinesis or neuroleptic malignant syndromes
• Severe physical problems
• pregnant or lactating women

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
HR	risperidone	risperidone 2mg/d + haloperidol 2mg/d

Primary Outcome Measures

Name	Time	Method
change from baseline in Positive and Negative Syndrome Scale (PANSS) total scores	6 weeks after the initiation of antipsychotic use

Trial Locations

Locations (1)

Kai-Suan Psychiatric Hospital; 🇨🇳 Kaohsiung, Taiwan